Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
/in Colorectal Cancer, Dendritic Cells, International PublicationsInitial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
/in Dendritic Cells, International PublicationsImmune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
/in Brain Tumors in Children, Dendritic Cells, International PublicationsImmunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease VirusPersonalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerOncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model
/in International Publications, Newcastle Disease VirusNewcastle disease virus strain AF2240 as an oncolytic virus: A review
/in International Publications, Newcastle Disease VirusWT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
/in Dendritic Cells, International Publications, Pancreatic CancerEffect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial
/in Hyperthermia, International Publications, Soft Tissue Sarcoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer